
LY 3200882
CAS No. 1898283-02-7
LY 3200882( LY3200882 )
Catalog No. M12981 CAS No. 1898283-02-7
LY 3200882 (LY3200882) is a novel potent, highly selective, ATP competitive TGF-β receptor type 1 (TGFβRI, ALK5) inhibitor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 58 | In Stock |
![]() ![]() |
5MG | 96 | In Stock |
![]() ![]() |
10MG | 152 | In Stock |
![]() ![]() |
25MG | 285 | In Stock |
![]() ![]() |
50MG | 462 | In Stock |
![]() ![]() |
100MG | 669 | In Stock |
![]() ![]() |
500MG | 1395 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameLY 3200882
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY 3200882 (LY3200882) is a novel potent, highly selective, ATP competitive TGF-β receptor type 1 (TGFβRI, ALK5) inhibitor.
-
DescriptionLY 3200882 (LY3200882) is a novel potent, highly selective, ATP competitive TGF-β receptor type 1 (TGFβRI, ALK5) inhibitor; potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells and in vivo in subcutaneous tumors; LY 3200882 shows potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment.Solid Tumors Phase 1 Clinical(In Vitro):LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells in a dose dependent fashion.LY3200882 shows potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment.In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naive T cell activity and restore proliferation.LY3200882 inhibits NIH3T3 cell viability with an IC50 of 82.9 nM.(In Vivo):LY3200882 (60 mg/kg; oral gavage; twice a day; for 21 days; BALB/C female mice) treatment significantly delays tumor growth in CT26 model.LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion.LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer).
-
In VitroLY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune cells in a dose dependent fashion. LY3200882 shows potent anti-tumor activity in the orthotopic 4T1-LP model of triple negative breast cancer and this activity correlated with enhanced tumor infiltrating lymphocytes in the tumor microenvironment.In in vitro immune suppression assays, LY3200882 has shown the ability to rescue TGFβ1 suppressed or T regulatory cell suppressed naive T cell activity and restore proliferation.LY3200882 inhibits NIH3T3 cell viability with an IC50 of 82.9 nM.
-
In VivoLY3200882 (60 mg/kg; oral gavage; twice a day; for 21 days; BALB/C female mice) treatment significantly delays tumor growth in CT26 model.LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vivo in subcutaneous tumors in a dose dependent fashion.LY3200882 has shown anti-metastatic activity in vivo in an experimental metastasis tumor model (intravenous EMT6-LM2 model of triple negative breast cancer). Animal Model:BALB/C female mice (5-8-week-old) injected with CT26 cells Dosage:60 mg/kg Administration:Oral gavage; twice a day; for 21 days Result:A statistically significant tumor growth delay in CT26 model was observed.
-
SynonymsLY3200882
-
PathwayTGF-beta/Smad
-
TargetTGFBR
-
RecptorTGF-beta/Smad
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1898283-02-7
-
Formula Weight435.528
-
Molecular FormulaC24H29N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 85 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCC(O)(C)C1=NC=CC(NC2=NC=CC(OC3=CN(C4CC4)N=C3C5CCOCC5)=C2)=C1
-
Chemical Name4-[[4-[[1-Cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy]-2-pyridinyl]amino]-α,α-dimethyl-2-pyridinemethanol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Huaxing Pei, et al. Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor. AACR. DOI: 10.1158/1538-7445.
molnova catalog



related products
-
LY 3200882
LY 3200882 (LY3200882) is a novel potent, highly selective, ATP competitive TGF-β receptor type 1 (TGFβRI, ALK5) inhibitor.
-
A77-01
A potent inhibitor of TGF-β type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.
-
Kartogenin
Kartogenin is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.